Abiopharma

News list

Lipocine Inc. (LPCN)

SEC News
Jan. 20, 2026, 14:31 UTC

(10% Negative) Lipocine Inc. (LPCN) Announces Delay in early Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text

News bot Jan. 29, 2026, 6:36 p.m.

📋 Lipocine Inc. (LPCN) - Clinical Trial Update

Filing Date: 2026-01-20

Accepted: 2026-01-20 09:31:25

Event Type: Clinical Trial Update

Event Details:

Lipocine Inc. (LPCN) Announces Clinical Trial Update Lipocine Inc. (LPCN) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: early, submission
Clinical Stage: Phase 3, Phase 3 trial
Update Type: Trial Timeline Adjustment
Primary Factors: Patient Enrollment, Regulatory Process
Collaboration: the U.S. Food and Drug Administration

🔬 Clinical Development Pipeline (Lipocine Inc.):

Product	Type	Development Stage	Therapeutic Area	Source
Placebo	DRUG	Phase PHASE3	Depression, Postpartum	ClinicalTrials.gov
LPCN 1154A	DRUG	Phase PHASE3	Depression, Postpartum	ClinicalTrials.gov
Topical testosterone gel 1.62 %	DRUG	Phase PHASE3	Male Hypogonadism	ClinicalTrials.gov
Oral testosterone undecanoate, LPCN 1021	DRUG	Phase PHASE3	Male Hypogonadism	ClinicalTrials.gov
LPCN 1021	DRUG	Phase PHASE3	Hypogonadism, Male	ClinicalTrials.gov
LPCN 1144	DRUG	Phase PHASE2	NASH - Nonalcoholic Steatohepatitis	ClinicalTrials.gov
LPCN 1144 Formulation B	DRUG	Phase PHASE2	Nonalcoholic Steatohepatitis (NASH)	ClinicalTrials.gov
LPCN 1144 Formulation A	DRUG	Phase PHASE2	Nonalcoholic Steatohepatitis (NASH)	ClinicalTrials.gov
LPCN 1148	DRUG	Phase PHASE2	Liver Cirrhosis	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Lipocine Inc.
Ticker Symbol: LPCN